Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure

Hippokratia

Volumn 12, Issue 1, 2008, Pages 22-27

  Sampanis, Ch ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Chronic kidney disease; Diabetes; Hyperglycemia therapy

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITRIOL; CALCIUM; DISOPYRAMIDE; ERYTHROPOIETIN; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; UREMIC TOXIN;

ANEMIA; CALCIUM CELL LEVEL; CALORIC INTAKE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTINUOUS INFUSION; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIALYSIS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; EXERCISE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; HYPERGLYCEMIA; HYPERPARATHYROIDISM; INSULIN DEGRADATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY FUNCTION; MEDICAL SPECIALIST; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERITONEAL DIALYSIS; PROTEIN RESTRICTION; REVIEW; SELF MONITORING; URINARY EXCRETION; VASCULAR DISEASE; WEIGHT REDUCTION;

EID: 39449103638     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231-2239
2. Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999; 282: 1519-1522
3. US Renal Data System. USRDS 1999 annual data report. Bethesda, Md. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 1999:25-38
4. Gerstein HC. Dysglycaemia: a cardiovascular risk factor. Diabetes Res Clin Pract 1998; 40(Suppl): 9-14
5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet 1998; 352: 837-853
6. Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with microvascular and macrovascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412
7. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003; 27 (Suppl 2) : s 21-s 23
8. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989; 4:859-863
9. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27:167-194
10. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 1984; 27: 351-357
11. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA. Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol 1983; 244: E517-E527
12. Rubenstein AH, Mako ME, Horowitz DL. Insulin and the kidney. Nephron 1975; 15: 306-326
13. Rabkin R, Simon NM, Steiner S, Colwell JA. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med 1970; 282:182-187
14. Katz AI, Rubenstein AH. Metabolism of proinsulin, insulin and C-peptide in rat. J Clin Invest 1973; 52: 1113-1121
15. Jaspen JB, Mako ME, Kuzuya H, Blix PM, Horowitz DL, Rubenstein AH. Abnormalities in circulating beta cell peptides in chronic renal failure: comparison of C-peptide, proinsulin and insulin. J Clin Endocrinol Metab 1977; 45: 441-446
16. Rave K, Heise T, Pfutzner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 2001; 24:886-890
17. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients. Diabet Med 2003; 20: 642-645
18. Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992; 61:377-382
19. Maack T, Johnson V, Kan ST, Figueiredo J, Sigulem D. Renal filtration, transport and metabolism of low molecular weight proteins: a review. Kidney Int 1979; 16: 251-270
20. Goldberg AP, Hagberg JM, Delmez JA, Haynes ME, Harter HR. Metabolic effects of exercise training in hemodialysis patients. Kidney Int 1980; 18: 754-761
21. Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int 1997; 52(Suppl) 62:S48-S52
22. Carone FA, Peterson DR. Hydrolysis and transport of small peptides by the proximal tubule. Am J Physiol 1980; 238: F151-158
23. Adrogui HJ. Glucose homeostasis and the kidney. Kidney Int 1992; 42:1266-1272
24. Mak RH. Intravenous 1,25-dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 1992; 41:1049-1054
25. Kautzsky-Willer A, Pacini G, Barnas U, et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995; 47:200-206
26. Lin S, Lin Y, Lu K, et al. Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin Sci 1994; 87:533-538
27. Borissova AM, Djambazova A, Todorov K, Dakovska L, Tankova T, Kirilov G. Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on hemodialysis. Nephrol Dial Transplant 1993; 8:93-98
28. Mak RH. Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. J Pediatr 1996; 129:97-104
29. Fadda GZ, Hajjar SM, Perna AF, Zhou XJ, Lipson LG, Massry SG: On the mechanism of impaired insulin secretion in chronic renal failure. J Clin Invest 1991; 87:255-261
30. Perna AF, Fadda GZ, Zhou XJ, Massry SG. Mechanisms of impaired insulin secretion after chronic excess of parathyroid hormone. Am J Physiol 1990; 259:F210-206
31. Oh H, Fadda GZ, Smogorzewski M, Liou HH, Massry SG. Abnormal leucine-induced insulin secretion in chronic renal failure. Am J Physiol 1994; 267:F853-860
32. Kokot F, Wiecek A, Grzeszczak W, Klin M, Zukovska-Szczechowska E. Influence of erythropoietin treatment on glucose tolerance, insulin, glucagon, gastrin, and pancreatic polypeptide secretion in hemodialyzed patients with end stage renal disease. Contrib Nephrol 1990; 87:42-51
33. Chagnac A, Weinstein T, Zevin D, et al. Effects of erythropoetin on glucose tolerance in hemodialysis patients. Clin Nephrol 1994; 42:398-400
34. Runyan JW, Hurwitz D, Robbins SL. Effect of Kimmelstiel-Wilson syndrome on insulin requirements in diabetes. N Engl J Med 1955; 252:388-391
35. Weinrauch LA, Healy RW, Leland OS Jr, et al. Decreased insulin requirements in acute renal failure in diabetic nephropathy. Arch Intern Med 1978; 138:399-400
36. Peitzman SJ, Agarwal BN. Spontaneous hypoglycemia in end stage renal failure. Nephron 1977; 19:131-139
37. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 1989; 18:103-121
38. Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis 2003; 41:523-531
39. de Boer MJ, Miedema K, Casparie AF. Glycosylated haemoglobin in renal failure. Diabetologia 1980; 18:437-440
40. Scott MG, Hoffman JW, Meltzer VN. Effects of azotemia on results of the boronate-agarose affinity method and in exchange methods for glycated hemoglobin. Clin Chem 1984; 30:896-898
41. Wettre S, Lundberg M. Kinetics of glycosylated hemoglobin in uremia determined on ion-exchange and affinity chromatography. Diabetes Res 1986; 3:107-110
42. Paisey R, Banks R, Holton R, et al. Glycosylated haemoglobin in uraemia. Diabet Med 1986; 3:445-448
43. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002;39:297-307
44. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM. Test of glycemia in diabetes. Diabetes Care 2004; 27 Suppl 1:S91-S93
45. Position statement. Standard of Medical Care in Diabetes-2007. Diabetes Care 2007; 30: s4-s41
46. Tzamaloukas AH, Murata GH, Zager PG, Eisenberg B, Avasthi PS. The relationship between glycemic control and morbidity and mortality for diabetics on dialysis. ASAIO J 1993; 39:880-885
47. Tzamaloukas AH. The use of glycosylated hemoglobin in dialysis patients. Semin Dial 1998; 11:143-147
48. Gin H, Rigaleau V, Aparicio M. Which diet for diabetic patients with chronic renal failure? Nephrol Dial Transplant 1999; 14:2577-2579
49. Gin H, Aparicio M, Aubertin J: Low protein and low phosphorus diet in patients with chronic renal failure: influence on glucose tolerance and tissue-insulin sensitivity. Metabolism 1987; 11:1080-1085
50. Gin H, Rigalleau V, Aparicio M: Which diet for diabetic patients with chronic renal failure? Nephrol Dial Transplant1999: 14:2577-2579
51. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004; 17:365-370
52. Arnoff GR, Berns JS, Brier ME. Drug prescribing in renal failure: dosing guidelines for adults, 4th ed. Philadelphia: American College of Physicians, 1999;
53. Skillman TG, Feldman JM. The pharmacology of sulphonylureas. Am J Med 1981; 70:361-372
54. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003; 26:886-891
55. Inoue T, Shibahara N, Miyagawa K et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003; 60 :90-95
56. Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycemia due to nateglinide in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 2003; 59: 191-194
57. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000; 26 (Suppl 4):73-85. K/D
58. Sambanis C, Tziomalos K, Kountana E, et al. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol 2007 (In press)
59. Sampanis Ch, Tziomalos K, Kehagia T, et al. Heart failure after thiazolidinedione therapy. Hippocratia 2005; 9: 8-91.
60. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 4(Suppl 3): S1-S360
61. Tunbridge FK, Newens A, Home PD, et al. A comparison of human ultralente- and lente-based twice-daily injection regimens. Diabet Med 1989; 6:496-501
62. Freeman SL, O'Brien PC, Rizza RA. Use of human ultralente as the basal insulin component in treatment of patients with IDDM. Diabetes Res Clin Pract 1991; 12:187-192
63. Diaz-Buxo JA. Blood glucose control in diabetics: I. Semin Dial 1993; 6:392-397
64. Daniels ID, Markell MS. Blood glucose control in diabetics: II. Semin Dial 1993; 6:394-399
65. Tzamaloukas AH, Oreopoulos DG. Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: a review. Adv Perit Dial 1991;7:81-85
66. Selgas R, Lopez-Riva A, Alvaro F, et al. Insulin influence on the mitogenic-induced effect of the peritoneal effluent in CAPD patients used as an additive to dialysate. Adv Perit Dial 1989; 5: 161-164